The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium; Daniel I Swerdlow; Michael V Holmes; Karoline B Kuchenbaecker; Jorgen E L Engmann; T Shah; R Sofat; Y Guo; C Chung; Anne Peasey; Nicholas J Timpson; Juan Pablo Casas

doi:10.1016/S0140-6736(12)60110-X

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium
, Daniel I Swerdlow
, Michael V Holmes
, Karoline B Kuchenbaecker
, Jorgen E L Engmann
, T Shah
, R Sofat
, Y Guo
, C Chung
, Anne Peasey
, Nicholas J Timpson
, Juan Pablo Casas

Research output: Contribution to journal › Article (Academic Journal) › peer-review

993 Citations (Scopus)

906 Downloads (Pure)

Abstract

A high circulating concentration of interleukin 6 is associated with increased risk of coronary heart disease. Blockade of the interleukin-6 receptor (IL6R) with a monoclonal antibody (tocilizumab) licensed for treatment of rheumatoid arthritis reduces systemic and articular inflammation. However, whether IL6R blockade also reduces risk of coronary heart disease is unknown.

Original language	English
Pages (from-to)	1214-1224
Number of pages	11
Journal	Lancet
Volume	379
Issue number	9822
Early online date	12 Mar 2013
DOIs	https://doi.org/10.1016/S0140-6736(12)60110-X
Publication status	Published - 31 Mar 2013

Access to Document

10.1016/S0140-6736(12)60110-X

Full-text PDF (final published version)
This is the final published version of the article (version of record). It first appeared online via Elsevier at http://www.sciencedirect.com/science/article/pii/S014067361260110X. Please refer to any applicable terms of use of the publisher.
Final published version, 321 KBLicence: CC BY
Supplementary information PDF
This is the final published version of the article (version of record). It first appeared online via Elsevier at http://www.sciencedirect.com/science/article/pii/S014067361260110X. Please refer to any applicable terms of use of the publisher.
Final published version, 4.97 MBLicence: CC BY

Handle.net

Persistent link

CENTRE FOR CASUAL ANALYSES IN TRANSLATIONAL EPIDEMIOLOGY (CAiTE)
Davey Smith, G. (Principal Investigator)
1/09/07 → 1/09/13
Project: Research

Cite this

Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Swerdlow, D. I., Holmes, M. V., Kuchenbaecker, K. B., Engmann, J. E. L., Shah, T., Sofat, R., Guo, Y., Chung, C., Peasey, A., Timpson, N. J., & Casas, J. P. (2013). The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet, 379(9822), 1214-1224. https://doi.org/10.1016/S0140-6736(12)60110-X

@article{c890020a99dc4482b03a7b6dea7a82e7,

title = "The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis",

abstract = "A high circulating concentration of interleukin 6 is associated with increased risk of coronary heart disease. Blockade of the interleukin-6 receptor (IL6R) with a monoclonal antibody (tocilizumab) licensed for treatment of rheumatoid arthritis reduces systemic and articular inflammation. However, whether IL6R blockade also reduces risk of coronary heart disease is unknown.",

author = "\{Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium\} and Swerdlow, \{Daniel I\} and Holmes, \{Michael V\} and Kuchenbaecker, \{Karoline B\} and Engmann, \{Jorgen E L\} and T Shah and R Sofat and Y Guo and C Chung and Anne Peasey and Timpson, \{Nicholas J\} and Casas, \{Juan Pablo\}",

year = "2013",

month = mar,

day = "31",

doi = "10.1016/S0140-6736(12)60110-X",

language = "English",

volume = "379",

pages = "1214--1224",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "9822",

}

Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Swerdlow, DI, Holmes, MV, Kuchenbaecker, KB, Engmann, JEL, Shah, T, Sofat, R, Guo, Y, Chung, C, Peasey, A, Timpson, NJ & Casas, JP 2013, 'The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis', Lancet, vol. 379, no. 9822, pp. 1214-1224. https://doi.org/10.1016/S0140-6736(12)60110-X

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. / Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium; Swerdlow, Daniel I; Holmes, Michael V et al.
In: Lancet, Vol. 379, No. 9822, 31.03.2013, p. 1214-1224.

Research output: Contribution to journal › Article (Academic Journal) › peer-review

TY - JOUR

T1 - The interleukin-6 receptor as a target for prevention of coronary heart disease

T2 - a mendelian randomisation analysis

AU - Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium

AU - Swerdlow, Daniel I

AU - Holmes, Michael V

AU - Kuchenbaecker, Karoline B

AU - Engmann, Jorgen E L

AU - Shah, T

AU - Sofat, R

AU - Guo, Y

AU - Chung, C

AU - Peasey, Anne

AU - Timpson, Nicholas J

AU - Casas, Juan Pablo

PY - 2013/3/31

Y1 - 2013/3/31

N2 - A high circulating concentration of interleukin 6 is associated with increased risk of coronary heart disease. Blockade of the interleukin-6 receptor (IL6R) with a monoclonal antibody (tocilizumab) licensed for treatment of rheumatoid arthritis reduces systemic and articular inflammation. However, whether IL6R blockade also reduces risk of coronary heart disease is unknown.

AB - A high circulating concentration of interleukin 6 is associated with increased risk of coronary heart disease. Blockade of the interleukin-6 receptor (IL6R) with a monoclonal antibody (tocilizumab) licensed for treatment of rheumatoid arthritis reduces systemic and articular inflammation. However, whether IL6R blockade also reduces risk of coronary heart disease is unknown.

U2 - 10.1016/S0140-6736(12)60110-X

DO - 10.1016/S0140-6736(12)60110-X

M3 - Article (Academic Journal)

C2 - 22421340

SN - 0140-6736

VL - 379

SP - 1214

EP - 1224

JO - Lancet

JF - Lancet

IS - 9822

ER -

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

Abstract

Access to Document

Handle.net

Fingerprint

Projects

CENTRE FOR CASUAL ANALYSES IN TRANSLATIONAL EPIDEMIOLOGY (CAiTE)

Cite this